---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-028339"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:26:25.639973+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex to spin out diabetes gene therapy program into new subsidiary GPX-002

## Summary
- Intends to transfer diabetes clinical development and gene therapy assets to wholly-owned NewCo.
- NewCo will focus on GPX-002 for Type 1 and Type 2 diabetes; Genprex retains oncology programs.
- Spin-out expected by end of 2024, subject to financing, conditions, and board approval.
- Reorganization follows recent refocus on oncology lead Reqorsa Gene Therapy for expedited regulatory submission.
- Company continues to evaluate strategic alternatives to enhance stockholder value.

## SEC filing metadata
- accession: 0001437749-24-028339
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924028339/0001437749-24-028339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924028339/gnpx20240703_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-028339
- JSON: https://secwatch.observer/filing/0001437749-24-028339.json
- Plain text: https://secwatch.observer/filing/0001437749-24-028339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.